Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534872 | 1.00 | AKT1 (0.53) | AKT1AKT2 | |
| SCHEMBL12451711 | 0.92 | AKT1 (0.52) | AKT1AKT2 | |
| SCHEMBL12841408 | 0.92 | AKT1 (0.46) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL1535079 | 0.91 | AKT1 (0.52) | AKT1AKT2 | |
| SCHEMBL12841502 | 0.90 | AKT1 (0.48) | AKT1AKT2 | |
| SCHEMBL1534943 | 0.90 | AKT1 (0.46) | AKT1AKT2 | |
| SCHEMBL1534892 | 0.89 | AKT1 (0.47) | AKT1AKT2 | |
| SCHEMBL1534905 | 0.89 | AKT1 (0.47) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL1534658 | 0.89 | AKT1 (0.45) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL1534567 | 0.88 | AKT1 (0.47) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546376-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-8546376-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-8546376-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-20120238541-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238541-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238541-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| EP-2473495-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011033265-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238541-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PLK1, MTOR | AKT1 6/4885AKT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.